Cover Image
Market Research Report

Global Cancer Tumor Organoids Modeling, Technology & Personalized Cancer Research Insight 2025

Published by KuicK Research Product code 920318
Published Content info 300 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Cancer Tumor Organoids Modeling, Technology & Personalized Cancer Research Insight 2025
Published: January 6, 2020 Content info: 300 Pages
Description

"Global Cancer Tumor Organoids Modeling, Technology & Personalized Cancer Research Insight 2025" Report Highlights:

  • Application of Organoids by Cancer Therapeutic
  • CRISPR-Cas9 Potential Applications in Cancer Organoids
  • Cancer Organoid Market Opportunity Assessment: >US$ 400 Million
  • Clinical Trials Registered under Cancer Organoids
  • Personalized Cancer Therapy Using Cancer Organoids
  • Joint Ventures to Accelerate Drug Discovery through Organoids

The development of cancer organoids has transformed the widespread adoption of the traditional 2D cell lines in the research community. The technology of cancer organoids holds a significant potential to study variety of areas such as cancer disease pathology, cancer biology, precision medicine, drug development, drug testing and drug efficacy testing. For the mentioned areas, cancer organoid technology constitutes tremendous informative complimentary approaches to the already available two-dimensional culture method and animal model system.

"Report Highlights The Ongoing Clinical Advancement In Cancer Organoids & Helps To Identify The Application Of Organoids Platform Across Multiple Cancers In Order To Develop More Personalized Cancer Therapy & Drug Screening"

On an average, the development of organoid culture represents a novel technology for studying human disease and human development. The ability of the organoids to resemble the original human tissue, form the correct type of cell and to perform the specific functions of the tissues helps in gaining the confidence of working on human cancer organoids and for the development of treatments against human cancers. Cancer organoids faithfully recapitulate the different aspects of tissue composition, function and architecture ex vivo and by doing so they set a great example of an advanced technology that comes with the possibility of opening up and identifying novel therapeutics strategies in personalizing the human disease model.

"The Organoid Technology Has The Advantage Of Predicting The Accurate Response Than Any Other 2D Cell Culture Models Available. It Carries Better Capacity To Unravel The Heterogeneity Within Individual Patients And Is Combined With High Throughput Screening Technology Than The Xenografts Model"

All this advancement should enable the cancer organoid technology to develop its place at the top and marking itself as an important tool in predicting the response of the cancer patients towards cancer treatment in the future. Till now, majority of the cancer organoids have been generated for adenocarcinomas and very less organoids are currently available for the squamous cell carcinomas. Since the development of cancer organoids from the cancer tumors in vivo, it has opened up new avenues for the investigation and identification of new drugs and treatments. As organoids can be developed from various types of cancer, therefore it offers a great potential towards investigating treatment responses in the patient personally and therefore is expected to provide a better insight into the precision medicine in the future.

For the future research, organoid technology is expected to present a crucial position and it is undoubtedly successful in revolutionizing the technical, preclinical and clinical techniques adapted in the laboratories. The technology of developing a complete organ in vitro from small amount of cells is considered as groundbreaking as the discovery of antibiotics, vaccines and chemotherapy in the fight against different human diseases. The technology requires few years and some advancement, to be dominant over the other available technologies.

Table of Contents

Table of Contents

1. Introduction to Organoids

  • 1.1. Organoids
  • 1.2. History of the Development
  • 1.3. Timeline for Patient Derived Tumor Organoid (PDTO) Development

2. Cancer Organoids: Promising Tool for Cancer Biologists

  • 2.1. Cancer Organoids Revealing the Cancer Dynamics
  • 2.2. Cancer Organoids: An Intermediate Platform for Targeted Therapy

3. Human Cancer Modeling

  • 3.1. Growth Factors & Small Molecule Inhibitors Applied In Organoid Cultures
  • 3.2. Culture Systems of Multiple Tumoroids
  • 3.3. Human Organoid Protocol
  • 3.4. Extraction Methods for Initiating an Organoid Generation
    • 3.4.1. Biopsy
    • 3.4.2. Surgery

4. Establishment of Cancer Organoids

  • 4.1. In-vitro Establishment of Stomach Cancer Organoid Cancer
  • 4.2. Invasion of In-Vivo Mutations in In-Vitro Organoid Model of Intestinal Cancer
  • 4.3. Expansion of Liver Cancer Organoids in the Laboratories
  • 4.4. In- Vitro Modeling of Pancreatic Cancer Organoid
  • 4.5. Transformation of Breast Cancer Cells into Organoids
  • 4.6. 3D Organoid Model Generation for Bladder Cancer
  • 4.7. Obtaining In-Vitro Model of In-Vivo Prostate Cancer
  • 4.8. Miniature Organ Development from the In-Vivo Ovarian Cancer Cells
  • 4.9. Creation of In-Vivo Esophageal Cancer as an In-Vitro Organoid Model

5. Cancer Organoids & Other Laboratory Techniques to Assess Treatment Responses

  • 5.1. Cell Lines
  • 5.2. Patient-Derived Xenografts
  • 5.3. Organotypic Tissue Slice Culture
  • 5.4. Cancer Organoids: Marking a New Territory

6. Tumors Organoids Accelerating Cancer Treatment

  • 6.1. Cancer Epidemic & Pre-Screening
  • 6.2. Cancer Organoids Predicting Tumor Responses

7. Advantages of Cancer Organoids

  • 7.1. Reduction in Experimental Complexity Through Cancer Organoids Models
  • 7.2. Similar Genetic Representation between the Organoid & Parent Tumor Organ
  • 7.3. Cancer Organoid Models Predicting the Response of Cancer Treatment
  • 7.4. Cancer Organoid Models Retaining the Phenotype of Parent Organ after Development
  • 7.5. Cancer Organoid Models Supporting Biomarker Profiling in Cancer Research

8. Cancer Organoids: Advanced Research & Therapeutic Potential

  • 8.1. Cancer Organoids: Revolutionizing Novel Anti-Cancer Drug Testing Methodology
  • 8.2. Mini-Organ Toxicity Demonstration by Cancer Organoids
  • 8.3. Pharmacokinetics & Pharmacodynamics Analysis Enabled by Cancer Organoids
  • 8.4. Cancer Organoids: Innovations in Drug Development Method
  • 8.5. Cancer Organoids as a Potential Platform for Personalized Cancer Therapy

9. Organoid Development Transforming Basic Medical Research

  • 9.1. Organoids Advancement in Organ Replacement
  • 9.2. Analyzing Gene Therapy on Organoids
  • 9.3. Organoids for Cell Therapy Analysis

10. Post-Model Generation Screening of Cancer Organoids

  • 10.1. Identical Genetic Characteristics between Cancer Organoid & Parent Organ
  • 10.2. Maintaining the Histology of Cancer Organ Tissues
  • 10.3. Tumorigenic Characteristic Screening of Cancer Organoids

11. Patient-Derived Tumor Organoids & its Achievement in Medical Research

  • 11.1. Translational Application of Cancer organoid Models
  • 11.2. Cancer Organoids Promoting Oncogenic Mutation Study
  • 11.3. Integration of the Microenvironment Induced by Cancer Organoids

12. CRISPR-Cas9 Potential Applications in Cancer Organoids

  • 12.1. CRISPR-Cas9: A Promising Gene Editing Technology
  • 12.2. CRISPR-Cas9 Mediated Cancer Organoid Technology
  • 12.3. CRISPR Based Gene Edited Organoids Recapitulating Cancer Mutations

13. Organoids for the Study of Pancreatic Cancer

  • 13.1. Human Endocrine & Exocrine Cancer Pancreatic 3D Model to Transform Cancer Treatment
  • 13.2. Development of Pancreas 3D Cancer Organoid System
  • 13.3. Applications of 3D Pancreatic Organoid Culture
    • 13.3.1. Pancreatic Cancer Organoid & Genetic Implementation
    • 13.3.2. Pancreatic Cancer Organoid & the Inner Environment Benefits
    • 13.3.3. Pancreatic Cancer Organoid Model for Drug Toxicity Screening
    • 13.3.4. Pancreatic Cancer Organoid Provoking Personalized Therapy

14. Organoids for the Study of Stomach Cancer

  • 14.1. Development of Stomach Cancer Organoid Culture
  • 14.2. High-Throughput Screening with Stomach Cancer Organoid 3D Model
    • 14.2.1. Tumorigenesis with Stomach Cancer Organoids
    • 14.2.2. Stomach Cancer Organoids Screening Drug Sensitivity
    • 14.2.3. Developing Stomach Cancer Biobanks for Drug Screening
    • 14.2.4. Stomach Cancer Organoids for Personalizing Therapy

15. Three-Dimensional Culture of Liver Organoid in Cancer Biology

  • 15.1. Development of Liver Organoids
  • 15.2. Progress & Potential of Organoid Towards Liver Cancer
    • 15.2.1. Liver Cancer Organoids as a New Model for Improving Drug Screening
    • 15.2.2. Primary Liver Cancer Organoids for Novel Drug Discovery
    • 15.2.3. Primary Liver Cancer Organoids Creating the Living Biobank for the Future Therapeutic Challenges
    • 15.2.4. Primary Liver Cancer Organoids Transforming Personalized Therapy

16. Advanced Development of Breast Cancer Organoids

  • 16.1. Organoid Technology to Transform Breast Cancer Modeling & Development
  • 16.2. An Organoid Approach Marking Breast Cancer Therapeutic Research
    • 16.2.1. Breast Cancer Organoids in Drug Development & Expansion
    • 16.2.2. Breast Cancer Organoids: An in-vitro Model for Cancer Biomarker Discovery
    • 16.2.3. Breast Cancer Organoids as a Powerful Resource for Personalized Therapy

17. Kidney Cancer Organoids for Cancer Research & Therapeutic Challenges

  • 17.1. Kidney Cancer Organoids: Developmental Approach & Characteristics Analysis
  • 17.2. Organoid Technology & its Applications in Treating Kidney Cancer
    • 17.2.1. Kidney Cancer Organoids Actively Participating in the Pre-Clinical & Clinical Trials
    • 17.2.2. Validation of Cancer Biomarkers by Kidney Cancer Organoids in Drug Development

18. Organoids for the Development of Lung Cancer

  • 18.1. Generation of Lung Cancer Organoid from Lungs Tissue
  • 18.2. Lung Cancer Organoids: A Novel 3D Platform for Therapeutic Research
    • 18.2.1. Lung Cancer Organoids for Therapeutic Screening & Cancer Research
    • 18.2.2. Organoids Re-Creating the Treatment for Lung Cancer

19. Ovarian Cancer Organoids & its role in Therapeutic Advancement

  • 19.1. Organoid Model Recapitulating Human Ovarian Cancer
  • 19.2. Validation of Potential Benefits Received from Patient-Derived Ovarian Cancer Organoid Model
    • 19.2.1. Editing of Oncogenes in the Patient Derived Ovarian Cancer Organoids
    • 19.2.2. Screening & Drug Testing on Human Ovarian Cancer Organoid Model
    • 19.2.3. Ovarian Cancer Organoids in Modeling the Ovarian Cancer Development & Progression

20. An Organoid Platform for Oncological Research in Bladder Cancer

  • 20.1. Establishment of High-Resolution 3D Organoid Model for Bladder Cancer
  • 20.2. Efficient Use of 3D Bladder Cancer Organoids in Oncology Landscape
    • 20.2.1. 3D Bladder Cancer Organoids at an Uprising Scale for Drug Discovery
    • 20.2.2. Testing & Screening of Drugs using Bladder Cancer Organoids
    • 20.2.3. Patient-Derived Bladder Cancer Organoids Predicting Response to Various Cancer Treatments

21. Human Primary Head & Neck Cancer: An Organoid Approach for In-depth Clinical Research

  • 21.1. Generation & Culture of 3D Head & Neck Cancer Organoids
  • 21.2. Patient-Derived Head & Neck Cancer Organoids Re-defining the Cancer Research
    • 21.2.1. Broad Activity of Head & Neck Cancer Organoids towards Cancer Modeling
    • 21.2.2. Transformation of Drug Development & Drug Efficacy Strategies in Head & Neck Cancer using Organoid Technology

22. Living Biobanks of Cancer Organoids Representing Histopathological Diversity

  • 22.1. The Potential of Living Biobank towards Precision Medicine
  • 22.2. Living Bio-banking Strategy Offering Novel Therapeutics for Basic & Advanced Cancer Research

23. Drivers & Challenges Associated with Cancer Organoids

  • 23.1. Drivers Witnessing the Growth of Cancer Organoid Technology
  • 23.2. Challenges Concerning the Growth of Cancer Organoids

24. Future Directions of Organoids in Cancer Research

25. Strategic Joint Ventures by Pharma Companies to Accelerate Drug Discovery through Organoids

  • 25.1. Expanded Breast Cancer Organoids License Agreement between Cellesce & Hubrecht Organoid Technology
  • 25.2. Pre-Clinical Anti-Cancer Drug Development between HUB Organoid Technology & Crown Biosciences
  • 25.3. SEngine's & Atomwise's New Joint Venture to Boost Drug Discovery through Organoids

26. Clinical Trials Registered under Cancer Organoids

  • 26.1. Lung Cancer
    • 26.1.1. Clinical Trial - Patient-Derived Organoids of Lung Cancer to Test Drug Responses
    • 26.1.2. Clinical Trial - Patient-Derived Organoid Model & Circulating Tumor Cell for Treatment Responses of Lung Cancer
    • 26.1.3. Clinical Trial - Drug Sensitivity Correlation between Patient-Derived Organoid Model & Clinical Responses in Non-Small Cell Lung Cancer Patients
  • 26.2. Breast Cancer
    • 26.2.1. Clinical Trial - Clinical Study on Drug Sensitivity Verification or Prediction for Breast Cancer by Patient-Derived Organoid Model
  • 26.3. Pancreatic Cancer
    • 26.3.1. Clinical Trial - Drug Screening of Pancreatic Cancer Organoids Developed from EUS-FNA Guided Biopsy Tissues
  • 26.4. Esophageal Cancer
    • 26.4.1. Clinical Trial - Chemoradioresistnace in Prospectively Isolated Cancer Stem Cells in Esophageal Cancer - Organoid: RARE STEM Organoid

27. Current Market Scenario of Cancer Organoid Technology

  • 27.1. Market Trends
  • 27.2. Market Overview
    • 27.2.1. North America
    • 27.2.2. Europe
    • 27.2.3. Asia-Pacific

28. Competitive Landscape

  • 28.1. Cellesce
  • 28.2. MIMETAS
  • 28.3. Hubrecht Organoid Technology
  • 28.4. Crown Biosciences
  • 28.5. Atomwise
  • 28.6. STEMCELL Technologies
  • 28.7. Qgel
  • 28.8. OcellO
  • 28.9. DefiniGEN

List of Figures

  • Figure 1-1: Organoid Culture Establishment
  • Figure 1-2: Timeline for PDTO Development
  • Figure 2-1: Strategy of Cancer Organoids
  • Figure 2-2: Cancer Organoid Establishment
  • Figure 2-3: Organoids Leading to Mutational Analysis of Cancer
  • Figure 2-4: Cancer Organoid as a Targeted Therapy
  • Figure 3-1: Human Organoid Development Protocol
  • Figure 3-2: Sample Collection through Biopsy
  • Figure 3-3: Sample Collection through Surgery
  • Figure 4-1: Developed Cancer Organoids
  • Figure 5-1: Available Methods for Cancer Assessment
  • Figure 5-2: Diagrammatic Representation of Currently Available Techniques
  • Figure 5-3: Establishment of Cultures through Cell Lines
  • Figure 5-4: Establishment of Patient-Derived Xenograft Models
  • Figure 5-5: Disadvantages of Patient-Derived Xenografts
  • Figure 5-6: Organotypic Tissue Slice Culture Preparation
  • Figure 5-7: Cancer Organoids Dominating Other Techniques
  • Figure 5-8: Characteristics of Cancer Organoid Model System
  • Figure 6-1: Pre-Screening Test Leading to Accelerated Cancer Treatment
  • Figure 7-1: Advantages of Cancer Organoids
  • Figure 7-2: Cancer Organoids Preserving Genetic Information
  • Figure 7-3: Cancer Organoids Predicting Cancer Treatment
  • Figure 7-4: Benefits of Preserving Phenotypic Characteristics by Cancer Organoids
  • Figure 7-5: Organoids & Human Organ Showing Similar Results
  • Figure 7-6: Biomarkers Application in the Medical World
  • Figure 7-7: Biomarkers Predicting Cancer Treatment Response
  • Figure 8-1: Applications of Cancer Organoids in Research
  • Figure 8-2: Difference Between 2D Screening & 3D Screening of Drugs
  • Figure 8-3: Cancer Organoids During the Detection of Drug Toxicity
  • Figure 8-4: Relationship between Pharmacokinetics & Pharmacodynamics
  • Figure 8-5: Benefits of Pharmacodynamics & Pharmacokinetics Analysis
  • Figure 8-6: Drug Discovery Cycle
  • Figure 8-7: Cancer Organoids during Drug Development
  • Figure 8-8: Personalized Cancer Therapy
  • Figure 8-9: Scientific Advances Leading to Personalized Therapy
  • Figure 8-10: Benefits of Personalized Therapy for the Patients
  • Figure 8-11: Personalized Cancer Therapy Using Cancer Organoids
  • Figure 9-1: Application of Organoids in Basic Medical Research
  • Figure 9-2: Process of Organ Donation
  • Figure 10-1: Post-Model Generation Screening Characteristics
  • Figure 10-2: Genetic Analysis of the Developed Organoid
  • Figure 10-3: Histological Maintenance of the Tumor Organoids
  • Figure 10-4: Characteristics of Tumor
  • Figure 11-1: Patient-Derived Tumor Organoids Progress Fields
  • Figure 12-1: Potential Applications of CRISPR-Cas9
  • Figure 12-2: Establishment of ESC or iPSC & ASC Derived Organoids
  • Figure 12-3: Applications of CRISPR Based Gene Edited Organoids
  • Figure 13-1: Generation & Applications of Pancreatic Cancer Organoid
  • Figure 13-2: Potential Applications of Organoid Derived from Pancreatic Cancer Cells
  • Figure 13-3: Personalized Therapy - Essential Requirements
  • Figure 14-1: Common Stomach Cancer Causing Agents
  • Figure 14-2: Human Stomach Cancer Organoid Culture
  • Figure 14-3: Applications of Stomach Cancer Organoids
  • Figure 15-1: Primary Liver Cancer Causing Diseases
  • Figure 15-2: Liver Organoids Derived from Tissue-Resident Stage & Embryonic Stage
  • Figure 15-3: Liver Organoids Derived from Induced Pluripotent Stem Cells
  • Figure 15-4: Post-Model Screening of Liver Organoid
  • Figure 15-5: Potential Applications of Primary Liver Cancer Organoids
  • Figure 15-6: Essential Requirements for Developing Personalized Vaccine
  • Figure 16-1: Risk Factors for Breast Cancer
  • Figure 16-2: Development of Breast Organoids
  • Figure 16-3: Applications of Breast Cancer Organoids in Breast Cancer Research
  • Figure 16-4: Steps for the Development of a Drug
  • Figure 16-5: Applications of Cancer Biomarkers
  • Figure 17-1: Risk Factors Associated with Renal Cell Carcinoma
  • Figure 17-2: Development of Kidney Cancer Organoids
  • Figure 17-3: Essential Requirements for Developing Kidney Cancer Organoids
  • Figure 17-4: Potential Applications of Kidney Cancer Organoids
  • Figure 17-5: Kidney Cancer Organoids for Studying Gene-Drug Association
  • Figure 17-6: Key Features of Cancer Biomarkers
  • Figure 18-1: Risk Factors Associated with Lung Cancer
  • Figure 18-2: Establishment of Lung Cancer Organoids
  • Figure 18-3: Characteristic Analysis for a Developed Organoid
  • Figure 18-4: Applications of Lung Cancer Organoids
  • Figure 18-5: Lung Cancer Organoids Towards Therapeutic Research
  • Figure 19-1: Risk Factors Associated with Prevalence of Ovarian Cancer
  • Figure 19-2: Human Ovarian Cancer Organoid Development
  • Figure 19-3: Characteristics Analysis of the In Vitro Model
  • Figure 19-4: Benefits of Developing Human Ovarian Cancer Organoid Model
  • Figure 20-1: Risk Factors & Symptoms Associated with Bladder Cancer
  • Figure 20-2: Establishment of Bladder Cancer Organoid
  • Figure 20-3: Characteristics Analysis for Developed Bladder Cancer Organoid
  • Figure 20-4: Key Applications of Bladder Cancer Organoids in Cancer Research
  • Figure 20-5: Dimensions for Personalized Medicine
  • Figure 20-6: Personalized Therapy
  • Figure 21-1: Risk factors & Symptoms Linked with the Development of Head & Neck Cancer
  • Figure 21-2: Generation of 3D Head & Neck Cancer Organoid
  • Figure 21-3: Characteristic Analysis of Developed Head & Neck Cancer Organoid
  • Figure 21-4: Key Applications of Head & Neck Cancer Organoids
  • Figure 21-5: Head & Neck Cancer Organoids Challenging Drug Development Strategies
  • Figure 22-1: Process of Bio-banking
  • Figure 22-2: Living Biobank of Organoid Allowing Different Experiments at Same Type
  • Figure 23-1: Drivers of Cancer Organoids
  • Figure 24-1: Future of Cancer Organoids
  • Figure 26-1: Start & Estimated Completion Date of the Clinical Trial
  • Figure 26-2: Start & Estimated Completion Date of the Clinical Trial
  • Figure 26-3: Start & Estimated Completion Date of the Clinical Trial
  • Figure 26-4: Start & Estimated Completion Date of the Clinical Trial
  • Figure 26-5: Start & Estimated Completion Date of the Clinical Trial
  • Figure 26-6: Start & Estimated Completion Date of the Clinical Trial
  • Figure 27-1: Market Share of Organoid by Applications
  • Figure 27-2: Global - Cancer Organoid Market Opportunity Assessment (US$ Million), 2020 -2025
  • Figure 27-3: Global - Percentage of New Cancer Cases, 2018
  • Figure 27-4: Global - Percentage of Cancer Deaths, 2018
  • Figure 27-5: United States - Companies Working on Organoid Technology
  • Figure 27-6: North America - Percentage of New Cancer Cases, 2018
  • Figure 27-7: North America - Percentage of New Cancer Cases in Males, 2018
  • Figure 27-8: North America - Percentage of New Cancer Cases in Females, 2018
  • Figure 27-9: USA - Percentage of New Cancer Cases, 2018
  • Figure 27-10: USA - Percentage of New Cancer Cases in Males, 2018
  • Figure 27-11: USA - Percentage of New Cancer Cases in Females, 2018
  • Figure 27-12: Canada - Percentage of New Cancer Cases, 2018
  • Figure 27-13: Canada - Percentage of New Cancer Cases in Males, 2018
  • Figure 27-14: Canada - Percentage of New Cancer Cases in Females, 2018
  • Figure 27-15: Mexico - Percentage of New Cancer Cases, 2018
  • Figure 27-16: Mexico - Percentage of New Cancer Cases in Males, 2018
  • Figure 27-17: Mexico - Percentage of New Cancer Cases in Females, 2018
  • Figure 27-18: US - Total Urothelial Cancer Drugs Market Size (US$ in Million), 2017 - 2018
  • Figure 27-19: Global Urothelial Cancer Drug Market Share, 2017
  • Figure 27-20: European Companies Working On Organoid Technology
  • Figure 27-21: Europe - Cancer Therapeutics Share by Type, 2018
  • Figure 27-22: Europe - Percentage of Cancer Cases, 2018
  • Figure 27-23: Europe - Percentage of Cancer Cases in Males, 2018
  • Figure 27-24: Europe - Percentage of Cancer Cases in Females, 2018
  • Figure 27-25: Germany - Percentage of Cancer Cases, 2018
  • Figure 27-26: Germany - Percentage of Cancer Cases in Males, 2018
  • Figure 27-27: Germany - Percentage of Cancer Cases in Females, 2018
  • Figure 27-28: United Kingdom - Percentage of Cancer Cases, 2018
  • Figure 27-29: United Kingdom - Percentage of Cancer Cases in Males, 2018
  • Figure 27-30: United Kingdom - Percentage of Cancer Cases in Females, 2018
  • Figure 27-31: France - Percentage of New Cancer Cases, 2018
  • Figure 27-32: France - Percentage of New Cancer Cases in Males, 2018
  • Figure 27-33: France - Percentage of New Cancer Cases in Females, 2018
  • Figure 27-34: Europe - Clinical Trial Market Value (US$ in Billion), 2018- 2024
  • Figure 27-35: Asia-Pacific - Clinical Trial Market Value (US$ in Billion), 2019 - 2024
  • Figure 27-36: Japan - Percentage of New Cancer Cases, 2018
  • Figure 27-37: Japan - Percentage of New Cancer Cases in Males, 2018
  • Figure 27-38: Japan - Percentage of New Cancer Cases in Females, 2018
  • Figure 27-39: China - Percentage of New Cancer Cases, 2018
  • Figure 27-40: China - Percentage of New Cancer Cases in Males, 2018
  • Figure 27-41: China - Percentage of New Cancer Cases in Females, 2018
  • Figure 27-42: India - Percentage of New Cancer Cases, 2018
  • Figure 27-43: India - Percentage of New Cancer Cases in Males, 2018
  • Figure 27-44: India - Percentage of New Cancer Cases in Females, 2018
  • Figure 27-45: South Korea - Percentage of New Cancer Cases, 2018
  • Figure 27-46: South Korea - Percentage of New Cancer Cases in Males, 2018
  • Figure 27-47: South Korea - Percentage of New Cancer Cases in Females, 2018

List of Tables

  • Table 3-1: Available Growth Factors & Molecule Inhibitors
  • Table 3-2: Available Culture Systems for Different Tumoroids
Back to Top